Where does Cyto365 AB rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cyto365 AB ranks #46,003 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cyto365 AB hold?

Cyto365 AB holds 5 US utility patents granted between 2017 and 2024, spanning 3 technology areas.

What is Cyto365 AB's Innovation Score?

Cyto365 AB has an Innovation Score of 22.8 out of 100 (11th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cyto365 AB's patent grant rate increasing or decreasing?

Cyto365 AB's recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cyto365 AB's patents?

Cyto365 AB's patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cyto365 AB patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cyto365 AB

Q: What technology areas does Cyto365 AB focus on?

Cyto365 AB's top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 5 patents, ranking #1,311 of 3,490 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cyto365 ranks #46,003 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.

#46,003
of 49,997 US assignees by volume: 11th percentile
by Innovation Score (22.8/100): 13.8
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R46003 · Foreign Corporation #46,003 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #46,003/49,997
PHOTO-FINISH Caddo Medical
CPC-NARROW A61M · 3 areas
INNOV-THIN 22.8/100
CLAIMS-RICH 13.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Caddo Medical Technologies LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cyto365’s 22.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (27%) Velocity 2.2 pts (10%) Breadth 6.1 pts (27%) Claim depth 8.3 pts (36%)

Qualcomm Incorporated · highest

85
Cyto365 AB · this assignee

23
3D Lighting… · lowest

7

What this shows Cyto365's Innovation Score is 22.8/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cyto365?

Each dot is one of Cyto365’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cyto365’s own 13.8 claims/patent is ABOVE the 12.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cyto365 vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cyto365's grants concentrate

Cyto365 AB is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2017. By volume, Cyto365 sits between Cymer-dayton, LLC and Cafe24 Corp..

Cyto365's three-year grant acceleration

Cyto365 AB shows 1 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cymer-dayton

5
Cymmetrik Enterpr…

5
Cyndrx

5
Cystech

5
Cytoaurora Biotec…

5
Caddo Medical

5
Caddy Products

5
Cafe24

5
Cyto365 AB ◀

5

What this shows Cyto365 holds 5 patents at rank #45,709, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cyto365

By rank, the assignees closest to #45,709 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Cyto365's primary technology class.

Cyto365's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

23 11th percentile higher than 11% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Cyto365 AB patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	20.0%
2019	2	40.0%
2021	1	20.0%
2024	1	20.0%

Which technologies does Cyto365 AB patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 5

F16K - VALVES; TAPS; COCKS; ACTUATING-FLOATS; Devices FOR Venting OR Aerating 4

Y10T - Technical Subjects Covered BY Former US Classification 1

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cyto365 AB's patent record in context - here's where to go next.

Cyto365 AB's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #46,003 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cyto365 AB against Cymer-dayton, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 22.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.